PIXIUM VISION news, videos and press releases
For more news please use our advanced search feature.
PIXIUM VISION - More news...
PIXIUM VISION - More news...
- Pixium Vision announces the opening of safeguard proceedings
- Pixium Vision announces the implementation of a bridge financing with Bpifrance and Sofinnova and a reverse stock split on the basis of 1 new share for 50 existing shares
- Pixium Vision announces the agreement to extend the maturity date of the outstanding notes associated with the terminated ESGO financing facility
- Annual Meeting of Shareholders June 13, 2023 / Availability of preparatory documents
- Pixium Vision announces its consolidated financial statements for the financial year 2022 and the consolidated cash balance for March 31, 2023
- Communication following the announcement of FDA Breakthrough Device Designation for the Prima System in Dry AMD
- Second convening of the Extraordinary Shareholder Meeting on March 8, 2023
- Pixium Vision welcomes judgment by Paris Commercial Court against Second Sight Medical Products
- Pixium Vision announces completion of implantations in the European pivotal trial PRIMAvera and confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024
- Pixium Vision announces its cash position at 30 September 2022 and provides an update on its activities
- Pixium Vision announces participation in investor conferences and events in October 2022
- Pixium Vision announces participation in upcoming investor conferences in September 2022
- Pixium Vision announces participation in upcoming scientific conferences in September 2022
- Pixium Vision to attend H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022
- Pixium Vision announces successful implantation of first patient in the Netherlands in Prima System European pivotal trial PRIMAvera
- Pixium Vision announces its financial results for H1 2022 and provides a business update
- Pixium Vision announces the availability of its audited financial statements for the financial year 2021
- Results of Combined General Meeting held on April 19, 2022
- Pixium Vision announces its cash position at 31 March 2022 and provides an update on its activities and financial outlook until the end of 2022
- Combined General Meeting of April 19, 2022: Availability of preparatory documents
- Pixium Vision announces FDA approval of clinical trial expansion of Prima System US feasibility study to Stanford Medicine
- Pixium Vision to participate in the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest on March 28 - 30
- Pixium Vision convenes a Combined General Meeting of Shareholders on April 19, 2022
- Pixium Vision announces its unaudited financial results for 2021 and provides a business update
- Pixium Vision announces the publication in Nature Communications of peer-reviewed clinical data demonstrating the clinical benefit of the Prima System in Dry AMD patients
- Pixium Vision to attend 11th Annual LifeSci Partners Corporate Access Event
- Pixium Vision gaining confidence in execution timeline of the PRIMAvera pivotal trial following first patient implantation in the UK
- Pixium Vision announces its cash position at 30 September 2021 and provides an update on its activities and financial outlook until the end of 2022
- Pixium Vision announces implantation of first patient in Germany in Prima System European pivotal trial PRIMAvera
- Pixium Vision expands collaboration with Stanford University on next generation Prima System implants